Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

98 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients.
Palumbo A, Gay F, Falco P, Crippa C, Montefusco V, Patriarca F, Rossini F, Caltagirone S, Benevolo G, Pescosta N, Guglielmelli T, Bringhen S, Offidani M, Giuliani N, Petrucci MT, Musto P, Liberati AM, Rossi G, Corradini P, Boccadoro M. Palumbo A, et al. Among authors: montefusco v. J Clin Oncol. 2010 Feb 10;28(5):800-7. doi: 10.1200/JCO.2009.22.7561. Epub 2010 Jan 4. J Clin Oncol. 2010. PMID: 20048187 Clinical Trial.
Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma.
Corradini P, Cavo M, Lokhorst H, Martinelli G, Terragna C, Majolino I, Valagussa P, Boccadoro M, Samson D, Bacigalupo A, Russell N, Montefusco V, Voena C, Gahrton G; Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Corradini P, et al. Among authors: montefusco v. Blood. 2003 Sep 1;102(5):1927-9. doi: 10.1182/blood-2003-01-0189. Epub 2003 May 8. Blood. 2003. PMID: 12738666 Free article. Clinical Trial.
Reduced-intensity conditioning containing low-dose alemtuzumab before allogeneic peripheral blood stem cell transplantation: graft-versus-host disease is decreased but T-cell reconstitution is delayed.
Dodero A, Carrabba M, Milani R, Rizzo E, Raganato A, Montefusco V, Farina L, Milanesi M, Longoni P, Carlo-Stella C, Corradini P. Dodero A, et al. Among authors: montefusco v. Exp Hematol. 2005 Aug;33(8):920-7. doi: 10.1016/j.exphem.2005.05.009. Exp Hematol. 2005. PMID: 16038785 Free article.
Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma.
van de Donk NW, Kröger N, Hegenbart U, Corradini P, San Miguel JF, Goldschmidt H, Perez-Simon JA, Zijlmans M, Raymakers RA, Montefusco V, Ayuk FA, van Oers MH, Nagler A, Verdonck LF, Lokhorst HM. van de Donk NW, et al. Among authors: montefusco v. Blood. 2006 Apr 15;107(8):3415-6. doi: 10.1182/blood-2005-11-4449. Blood. 2006. PMID: 16597603 Free article. No abstract available.
Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma.
van de Donk NW, Kröger N, Hegenbart U, Corradini P, San Miguel JF, Goldschmidt H, Perez-Simon JA, Zijlmans M, Raymakers RA, Montefusco V, Ayuk FA, van Oers MH, Nagler A, Verdonck LF, Lokhorst HM. van de Donk NW, et al. Among authors: montefusco v. Bone Marrow Transplant. 2006 Jun;37(12):1135-41. doi: 10.1038/sj.bmt.1705393. Bone Marrow Transplant. 2006. PMID: 16757975
Unrelated donor haematopoietic cell transplantation after non-myeloablative conditioning for patients with high-risk multiple myeloma.
Bruno B, Sorasio R, Patriarca F, Montefusco V, Guidi S, Busca A, Scimé R, Console G, Milone G, Marotta G, Dominietto A, Giaccone L, Rotta M, Falda M, Bacigalupo A, Bosi A, Corradini P, Fanin R, Pollichieni S, Boccadoro M; Gruppo Italiano Trapianto Midollo Osseo. Bruno B, et al. Among authors: montefusco v. Eur J Haematol. 2007 Apr;78(4):330-7. doi: 10.1111/j.1600-0609.2007.00816.x. Epub 2007 Feb 27. Eur J Haematol. 2007. PMID: 17331132 Clinical Trial.
Bortezomib after allografting in multiple myeloma: association between neurotoxicity and cyclosporine treatment.
Giaccone L, Sorasio R, Patriarca F, Mattei D, Montefusco V, Peccatori J, Carnevale-Schianca F, Petrucci MT, Milone G, Guidi S, Rotta M, Fanin R, Corradini P, Boccadoro M, Bruno B. Giaccone L, et al. Among authors: montefusco v. Biol Blood Marrow Transplant. 2007 Apr;13(4):497-9. doi: 10.1016/j.bbmt.2007.01.069. Biol Blood Marrow Transplant. 2007. PMID: 17382258 Free article. Clinical Trial. No abstract available.
98 results